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Abstract
Of the 47 prefectures in Japan, Iwate had the fewest cases of coronavirus disease 2019 (COVID-19), 
with the first diagnosis officially confirmed on July 28, 2020. A baseline serological survey of COV-
ID-19 antibodies is essential to accurately evaluate an epidemic outbreak. The primary purpose of 
this study was to determine pre-epidemic prevalence of COVID-19 antibodies among healthcare 
workers, using two laboratory-based quantitative tests. In addition, a point-of-care (POC) qualita-
tive test, rapid, simple, and convenient for primary care clinics, was compared with the laboratory-
based tests. All antibody tests were performed on serum from 1,000 healthcare workers (mean 
age, 40 ± 11 years) in Iwate Prefectural Central Hospital, May 29-31, 2020. A COVID-19 case was 
defined as showing positive results in both laboratory-based quantitative tests. None of 1,000 sam-
ples had positive results in both of the laboratory immunoassays. The POC test showed positive 
results in 33 of 1,000 samples (3.3%) (95% confidence interval : 2.19-4.41), but no samples were si-
multaneously positive in both laboratory-based tests. In conclusion, COVID-19 cases were not se-
rologically confirmed by a baseline control study of healthcare workers at our hospital in late May, 
2020. Moreover, the POC qualitative test may offer no advantage in areas with very low prevalence 
of COVID-19, due to higher false-positive reactions compared with laboratory-based quantitative 
immunoassays.
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Coronavirus disease 2019 (COVID-19), caused 
by the severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2), has spread rapidly worldwide, 
affecting human health and social life1-3). In Japan, 
the first COVID-19 case was confirmed in January 
2020, and the total number of cases had reached 
83,010 as of September 30, 20204). Among the 47 
prefectures of Japan, only Iwate, a northeastern pre-
fecture with a population of 1,227,647 (as of April 
2020), had no reported COVID-19 cases until the 
first confirmed diagnosis on July 28, 2020, rising 
only to 23 cases as of September 30, 20205).
To prevent in-hospital infection spread, a sero-
logical survey for COVID-19 among frontline health-
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care workers, at high risk of exposure, may be bene-
ficial6). However, the true prevalence of COVID-19 
remains unclear in Iwate because limited availability 
of real-time reverse transcriptase-polymerase chain 
reaction (RT-PCR) diagnostic tests made it likely 
that some asymptomatic cases would be missed.　
Pre-epidemic prevalence of COVID-19 antibodies 
would allow comparisons with subsequent data to 
estimate infection trends and better address the 
health and social issues brought about by COVID-19. 
An orthogonal testing strategy with two or more 
laboratory-based quantitative immunoassays with 
very high specificity (99.5% or greater) has been 
useful in populations with a very low prevalence of 
COVID-197). Simpler point-of-care (POC) antibody 
tests are useful in areas with a high-prevalence of 
COVID-198). However, inadequate specificity may 
be problematic in low-prevalence areas, and their ef-
ficacy has not been studied in areas with no reported 
cases.
The primary purpose of this study was to inves-
tigate the prevalence of COVID-19 antibodies among 
healthcare workers at a tertiary hospital in north-
eastern Japan - where no official cases had been 
confirmed prior to July 28, 2020 - using two labora-
tory-based, high-specificity tests in an orthogonal 
analysis. Additionally, we also compared the accu-
racy of POC antibody tests with that of the quantita-
tive COVID-19 antibody tests.
Materials and methods
Study design
Iwate Prefecture, with 1.2 million residents, is 
on the Pacific coast of northeastern Japan. To de-
termine the seroprevalence of COVID-19 in our re-
gion, we retrospectively evaluated COVID-19 anti-
bodies in serum from healthcare workers at Iwate 
Prefectural Central Hospital in the city of Morioka 
(Figure 1). The hospital, which has 685 beds, with 
a daily average of 1,100 outpatients and 534 inpa-
tients in 2019, is one of the core medical institutions 
in Iwate Prefecture.
The study protocol was approved by the ethics 
committee of Iwate Prefectural Central Hospital, 
Iwate, Japan (approval number 343), in accord with 
the World Medical Association Declaration of Hel-
sinki.
Study population and antibody tests
Blood samples were obtained from the annual 
Fig. 1. The location of Iwate Prefecture and Iwate Prefectural Central Hospital. Number of COVID-19 cases by 
prefecture as of May 31, 2020, based on statistics from the Japanese Ministry of Health, Labour and Welfare (Ref. 
4).
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health checkups of 1,302 healthcare workers (physi-
cians, nurses, pharmacists, radiographers, laboratory 
technicians, and medical office workers) on May 18-
29, 2020, and stored at −20°C. Serum samples (n 
= 1,000) from employees from whom informed con-
sent was obtained were analyzed for antibodies to 
SARS-CoV-2 using laboratory-based quantitative 
and POC qualitative tests on May 29-31, 2020.
Two laboratory-based quantitative tests that 
were approved by the US Food and Drug Adminis-
tration were used : Abbott Architect® SARS-CoV-2 
IgG Assay (chemiluminescent microparticle immu-
noassay ;  sensitivity, 100% ; specificity, 99.6%) (Ab-
bott Laboratories, Abbott Park, IL, USA)7) and Roche 
Elecsys® Anti-SARS-CoV-2 RUO Assay (electro-
chemiluminescent immunoassay ; sensitivity, 
100% ;  specificity, 99.8%) (Roche Diagnostics, Ba-
sel, Switzerland)7). POC qualitative testing was 
performed with the Instant-view® IgG/IgM Antibody 
COVID-19 test (lateral flow chromatographic immu-
noassay ;  sensitivity, 97.8% ; specificity, 94.6%) 
(Alfa Scientific Designs, Poway, CA, USA).　All 
tests were conducted at room temperature and ac-
cording to each manufacturer’s instructions. Re-
sults were read visually after 10 minutes. Weak 
signals for IgM and IgG indicated a positive result.
A diagnosis of COVID-19 infection was made 
only if positive in both laboratory-based immunoas-
says ;  a sample receiving only one positive result 
was considered noninfected. The prevalence of 
COVID-19 was determined by dividing the number 
of infected cases by that of samples. Continuous 
variables were expressed as mean ± SD, and cate-
gorical variables were expressed as numbers and 
percentages. The 95% confidence intervals (95% 
CIs) for the positive results in the tests were pre-
sented by the Wald method using Microsoft Excel.
Results
A total of 1,000 serum samples (from 264 men 
and 736 women ; mean age, 40 ± 11 years) were 
analyzed in this study. The laboratory-based im-
munoassays detected positive results in 4 of 1,000 
samples (0.4%) (95% CI, 0.01-0.79) : Abbott’s assay 
in 4 samples (0.4%) (95% CI, 0.01-0.79) and Roche’s 
assay in 0 (0%) (Table 1). According to the study 
design that required positive results in both tests, no 
cases were confirmed positive (Table 2).
In contrast to the quantitative immunoassays, 
the POC qualitative test showed positive results 
with 33 of 1,000 samples (3.3%) (95% CI, 2.19-4.41). 
No sample had a positive result in both laboratory 
Table 1.  Results of the POC qualitative and laboratory-






Alfa POC test Abbott’s Assay
Roche’s 
Assay
Sample number IgM IgG IgG IgM + IgG
22 N P N N
28 P N N N
32 P N N N
149 P N N N
169 P N N N
227 P P N N
262 P N N N
284 P N N N
286 P N N N
306 N P N N
374 N P N N
382 P N N N
393 P N N N
399 P N N N
409 P N N N
445 P N N N
498 N P N N
545 P P N N
552 N P N N
558 P N N N
571 N P P N
576 N N P N
634 P N N N
694 N P N N
698 P N N N
700 P N N N
726 N N P N
830 N N P N
857 P N N N
882 N P N N
885 P N N N
887 P N N N
904 P N N N
908 P N N N
914 P N N N
926 P P N N







CI, confidence interval ; COVID-19, coronavirus dis-
ease 2019 ; N, negative ; P, positive ; POC, point-of-
care.
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and POC tests (Table 1).
Discussion
To the best of our knowledge, this is the first 
study to evaluate the positivity rate of antibodies to 
SARS-CoV-2 in a region that had no officially con-
firmed cases of COVID-19 infection, data that would 
be necessary to meaningfully assess infection status 
after the epidemic. We qualitatively and quantita-
tively tested for SARS-CoV-2 antibodies in serum 
using two immunoassays and a POC test and found 
the following results. First, there were no positive 
results detected by both laboratory-based (Abbott 
and Roche) quantitative immunoassays. Second, 
because there were no positive results in Roche’s 
assay, the results from the POC test were consid-
ered false positives. These results argue against 
using low-specificity COVID-19 antibody testing in 
an area with no known infection.
The COVID-19 epidemic in Japan reached its 
first peak on April 11, 2020, with a daily number of 
714 new infected cases4). As of May 29, when 
blood sampling in this study concluded, the total 
number of cases in Japan was 16,650, of whom 891 
individuals had died4). After the first peak on April 
11, the number of daily COVID-19 cases gradually 
decreased and returned to January’s early-onset lev-
els. The overall number of infected cases was rela-
tively small compared with those in other developed 
countries.
With the decline in cases in Japan, the focus has 
shifted from widespread testing for active COV-
ID-19 to testing for antibodies. The serological 
tests to detect COVID-19 antibodies are crucial for 
individuals and to monitor the spread of the virus.　
In New York State, USA, which had an explosive 
growth of infections and was deemed an epicenter in 
early May 2020, the prevalence of COVID-19 was as 
high as 10%-15%8). Areas where the spread was 
relatively suppressed, such as Los Angeles County, 
California, USA, had rates <5%9). However, high 
rates in the USA shifted from New York to other re-
gions in the early summer of 2020.
In Japan, the positive rate of COVID-19-specific 
IgG antibodies was 3.3% in 1,000 outpatients who 
visited Kobe City Medical Center General Hospi-
tal10). Blood samples obtained from 202 patients at 
community clinics in Tokyo showed a 5.9% rate of 
infection11). In late April, the Japanese Ministry of 
Health, Labour and Welfare (MHLW) examined the 
performance of five commercially available antibody 
test kits with donated blood collected in the Tohoku 
region (6 northeastern prefectures, including Iwate).　
This analysis showed that COVID-19 antibodies 
were detected in 2 of 500 samples, with a positive 
rate of 0.4%4). These data and our results suggest 
a low prevalence of COVID-19 in the Tohoku region, 
including our prefecture, compared with rates in To-
kyo and Kobe City. Our results were also compati-
ble with those of another MHLW antibody survey in 
Iwate’s neighboring prefecture of Miyagi, which 
showed only a 0.03% positive rate4).
Among the 47 prefectures in Japan, only Iwate 
had no reported COVID-19 cases until Iwate’s first 
case was confirmed on July 28, 20205) ; it is probably 
rare for state-sized regions in other countries to be 
similarly without cases. As of May 29, over 6,000 
inquiries for RT-PCR tests had been made to a local 
hotline from concerned individuals ; however, Iwate 
conducted only 730 tests, the lowest level in Japan5).
While Iwate had no hospitalized cases of COV-
ID-19, the prefecture had a very difficult time ob-
taining RT-PCR tests in the early weeks of the epi-
demic. Since neighboring prefectures such as 
Miyagi and Aomori4) already had COVID-19 cases, 
Iwate possibly had cases, but they were not diag-
nosed due to the unavailability of tests. Through-
out Japan, tests were initially reserved for symptom-
atic individuals or those with known exposure. In 
Iwate, test requests had to be approved by health-
care personnel, at least through the end of April.
Our hospital is in Morioka, the capital city of 
Iwate, and provides high-level medical research and 
services for the region’s population. We connect 
with other clinics and hospitals through a medical 
network and play a central role in disease treatment 
and prevention. When the state of emergency was 
declared by Japan’s Prime Minister on April 712), 
Iwate’s residents were urged to stay in their homes.　
Because residents were not available for random 
blood-sample testing, we determined the prevalence 
of COVID-19 in our region by testing our hospital’s 
healthcare workers. As of August 7, 2020, Japan 
had entered a second wave, with a daily number of 





    Positive 0 (0%)     4 (0.4%)     4 (0.0%)
    Negative 0 (0%)   996 (99.6%)   996 (99.6%)
    Total 0 (0%) 1,000 (100%) 1,000
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1,618 new infections and cumulative total of 44,770 
cases4). In Iwate, the first case was reported on 
July 29, 2020, and 23 cases were diagnosed by Sep-
tember 30, 20205). We considered that this testing 
would be essential to assess nosocomial infection 
and provide data to prevent the spread of infection 
and occurrence of the second wave of COVID-19.　
Furthermore, we believe that our study will provide 
data to inform epidemic models and make public pol-
icy decisions.
Several commercial COVID-19 antibody immu-
noassays are now available. In a region with very 
low prevalence, an antibody test with a high specific-
ity (perhaps ≥ 99.5%) should be used, which would 
yield a higher positive predictive value13). This 
study’s quantitative tests had a high specificity 
(99.6% and 99.8% in Abbott’s and Roche’s assays, 
respectively), and positive results were only detect-
ed in four (0.4%) samples in the former and no sam-
ples in the latter. There were more false-positive 
COVID-19 antibody results in the POC qualitative 
test, whose specificity was relatively low (94.6%).　
Antibody tests with high accuracy and consistent 
performance are needed not only in Iwate Prefec-
ture but also throughout Japan to determine the 
prevalence of COVID-19.
This study has several limitations. First, it 
was a survey from a single medical institution with a 
relatively small number of blood samples. The par-
ticipants in this study were healthcare workers ; 
thus, younger or older individuals were not enrolled.　
Second, positive and negative control tests are sig-
nificant for the full validation of COVID-19 antibod-
ies and assessment of nonspecific binding. In this 
study, attempts to use a positive or negative control 
test presented difficulties because of no identified 
infected cases and a stay-at-home order that affect-
ed the population. Third, the timing of COVID-19 
antibody tests may be significant for accurate COV-
ID-19 antibody detection. Because recent reports 
show the disappearance of antibody or a decrease in 
the titer after COVID-19 infection14,15), repeated 
measurements of antibody would be warranted after 
a potent epidemic. Fourth, the POC tests for COV-
ID-19 antibody are unreliable, and the development 
of accurate tests is essential as an epidemiological 
tool.
Conclusions
The baseline seroprevalence of COVID-19 anti-
bodies was 0% among our hospital’s healthcare 
workers. If this group can be taken as a represen-
tative sample of the population at large, our results 
suggest that Iwate Prefecture was unaffected by 
COVID-19 for a longer period than other Japanese 
prefectures. Such areas, with a low prevalence of 
COVID-19 cases, need tests with high specificity. 
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